Let's Talk MS from MS-UK

Let's Talk MS Medical cannabis and low-dose naltrexone

October 18, 2023 MS-UK Season 1 Episode 3
Let's Talk MS Medical cannabis and low-dose naltrexone
Let's Talk MS from MS-UK
More Info
Let's Talk MS from MS-UK
Let's Talk MS Medical cannabis and low-dose naltrexone
Oct 18, 2023 Season 1 Episode 3
MS-UK

How helpful is cannabis-based medication for people with multiple sclerosis? Ian Cook speaks to Professor Mike Barns, Chief Medical Officer at Drug Science, a group which works to provide an evidence base free from political or commercial influence. Proff Barns explains the work they are doing to make accessing cannabis-based medicine easier to access for people with multiple sclerosis, and how it can benefit patients.

We also hear from an MS patient who has been prescribed Sativex, a licenced cannabis-based medication, and their experiences with it.

Low-dose naltrexone is an off-licence medication that some people with MS say improves their symptoms. Linda Elsegood is the founder of The LDN Trust and has made it her life's work to try to get people with MS access to this drug. She tells Ian how the treatment completely changed her life. 


Show Notes

How helpful is cannabis-based medication for people with multiple sclerosis? Ian Cook speaks to Professor Mike Barns, Chief Medical Officer at Drug Science, a group which works to provide an evidence base free from political or commercial influence. Proff Barns explains the work they are doing to make accessing cannabis-based medicine easier to access for people with multiple sclerosis, and how it can benefit patients.

We also hear from an MS patient who has been prescribed Sativex, a licenced cannabis-based medication, and their experiences with it.

Low-dose naltrexone is an off-licence medication that some people with MS say improves their symptoms. Linda Elsegood is the founder of The LDN Trust and has made it her life's work to try to get people with MS access to this drug. She tells Ian how the treatment completely changed her life.